Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137888 · ClinicalTrials.gov registry record · Phase 2
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03137888 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT03137888, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyond current clinical MRI scans by mapping areas of high tumor metabolism. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Spectroscopic MRI-guided radiation therapy may work better in treating patients with glioblastoma or gliosarcoma.
Interventions
- DRUG Temozolomide
- RADIATION Dose-Escalated Radiation Therapy
- PROCEDURE Spectroscopic Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137888
The ClinicalTrials.gov registry entry for NCT03137888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT03137888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137888 about?
NCT03137888 is a clinical study titled "Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma". This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyo...
What is the current status of trial NCT03137888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-09-20. Estimated completion is 2024-09-09.
What interventions are being tested in trial NCT03137888?
The interventions under investigation include: Temozolomide (DRUG), Dose-Escalated Radiation Therapy (RADIATION), Spectroscopic Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03137888?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.